Telli, M. L., Ruiz-Borrego, M., Yonemori, K., Zhao, Y., Jhaveri, K. L., Wang, S., Patnaik, A., Frenel, J., Xu, P., Tran, L., Lonning, S., Berkowitz, N. C., Zhang, Y., Mazzoletti, M., Mukohara, T. (2026). Vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus atirmociclib (ATI) in ER+/HER2− advanced breast cancer (ABC): TACTIVE-K phase 1b/2 results.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1075